Literature DB >> 20600078

Efficiency of different strategies to detect autoantibodies to extractable nuclear antigens.

Delia Almeida González1, Antonio Cabrera de León, María Del Cristo Rodríguez Pérez, Buenaventura Brito Díaz, Ana González Hernández, Diego García García, Carmen Vázquez Moncholi, Armando Aguirre Jaime.   

Abstract

Autoantibodies to extractable nuclear antigens (anti-ENA) are identified mainly in samples positive for antinuclear antibodies (ANA). Although the method of choice for ANA screening is indirect immunofluorescence (IIF), several techniques are available to detect anti-ENA. The aim of this study was to compare the efficiency of five different strategies to determine anti-ENA. During a 2-year period we screened ANA in 30375 samples with IIF, and the 4475 samples ANA positive were tested for anti-ENA by double immune diffusion screening or fluoroenzymeimmunoassay (Screening FI); anti-ENA specificities were then determined by line immunoassay (LIA) or fluoroenzymeimmunoassay (FI). We compared five strategies that involved FI or LIA identification of anti-ENA with or without prior screening, or an algorithm that combined fluorescence pattern, number of anti-ENA specificities requested by the clinician and ANA dilution titer. One cost unit (CU) was defined as the cost of 1 test of ANA determination. We detected 553 anti-ENA positive samples. The most efficient strategy was the algorithm, at a cost of 3.3 CU per sample processed, the second most efficient strategy was screening plus FI identification (cost=3.8 CU), and the third most efficient strategy was screening plus LIA identification (cost=3.9 CU). The fourth most efficient strategy was FI identification without prior screening (13.3 CU per sample) and the least efficient was LIA identification without prior screening (13.6 CU per sample). In conclusion, an algorithm that combined techniques for detection, ANA titer, fluorescence pattern and number of specificities requested was the most efficient strategy for determining anti-ENA. 2010 Elsevier B.V. All rights reserved.

Mesh:

Substances:

Year:  2010        PMID: 20600078     DOI: 10.1016/j.jim.2010.06.013

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  8 in total

1.  New automated indirect immunofluorescent antinuclear antibody testing compares well with established manual immunofluorescent screening and titration for antinuclear antibody on HEp-2 cells.

Authors:  M Daves; J Blecken; T Matthias; A Frey; V Perkmann; A Dall Acqua; A Joos; S Platzgummer
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

2.  Comparative study of immunofluorescent antinuclear antibody test and line immunoassay detecting 15 specific autoantibodies in patients with systemic rheumatic disease.

Authors:  Sun Ah Lee; Jimin Kahng; Yonggoo Kim; Yeon-Joon Park; Kyungja Han; Seung-Ki Kwok; Sung-Hwan Park; Eun-Jee Oh
Journal:  J Clin Lab Anal       Date:  2012-07       Impact factor: 2.352

Review 3.  Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies.

Authors:  Michael Mahler; Pier-Luigi Meroni; Xavier Bossuyt; Marvin J Fritzler
Journal:  J Immunol Res       Date:  2014-04-27       Impact factor: 4.818

Review 4.  Emerging technologies in autoantibody testing for rheumatic diseases.

Authors:  Nancy J Olsen; May Y Choi; Marvin J Fritzler
Journal:  Arthritis Res Ther       Date:  2017-07-24       Impact factor: 5.156

5.  Comparison of antinuclear antibody profiles obtained using line immunoassay and fluorescence enzyme immunoassay.

Authors:  Jaehyeok Jang; Sinyoung Kim; Hyon-Suk Kim; Kyung-A Lee; Jungyong Park; Younhee Park
Journal:  J Int Med Res       Date:  2021-06       Impact factor: 1.671

6.  Automated indirect immunofluorescence evaluation of antinuclear autoantibodies on HEp-2 cells.

Authors:  Jörn Voigt; Christopher Krause; Edda Rohwäder; Sandra Saschenbrecker; Melanie Hahn; Maick Danckwardt; Christian Feirer; Konstantin Ens; Kai Fechner; Erhardt Barth; Thomas Martinetz; Winfried Stöcker
Journal:  Clin Dev Immunol       Date:  2012-11-11

7.  Confirmation of anti-DFS70 antibodies is needed in routine clinical samples with DFS staining pattern.

Authors:  Esvet Mutlu; Mete Eyigör; Derya Mutlu; Meral Gültekin
Journal:  Cent Eur J Immunol       Date:  2016-03-24       Impact factor: 2.085

8.  Relationships among Antibodies against Extractable Nuclear Antigens, Antinuclear Antibodies, and Autoimmune Diseases in a Brazilian Public Hospital.

Authors:  Fernanda Weyand Banhuk; Bruna Corrêa Pahim; Alex Sandro Jorge; Rafael Andrade Menolli
Journal:  Autoimmune Dis       Date:  2018-09-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.